Acasti Pharma logo

Acasti PharmaNASDAQ: ACST

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

07 February 2012

Next earnings report:

13 November 2024

Last dividends:

N/A

Next dividends:

N/A
$31.43 M
-59%vs. 3y high
29%vs. sector
-vs. 3y high
-vs. sector
-23%vs. 3y high
29%vs. sector
-vs. 3y high
-vs. sector

Price

regular market | Fri, 01 Nov 2024 13:30:00 GMT
$3.10-$0.10(-3.12%)

Dividend

No data over the past 3 years
No data over the past 3 years

Analysts recommendations

Institutional Ownership

ACST Latest News

Acasti Announces Corporate Name Change to Grace Therapeutics, Inc.
globenewswire.com25 October 2024 Sentiment: POSITIVE

Name Change Reflects Extensive Scientific and Corporate Brand Equity Previously Established under Grace Therapeutics Grace Therapeutics will begin trading on Nasdaq under the trading symbol "GRCE" effective October 28, 2024 Virtual Key Opinion Leader Event to be held on November 20 th PRINCETON, N.J., Oct. 25, 2024 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (Nasdaq: ACST) (Acasti or the Company), a late-stage, biopharma company advancing GTx-104, its novel injectable formulation of nimodipine that addresses high unmet medical needs for a rare disease, aneurysmal subarachnoid hemorrhage (aSAH), today announced that it is changing its name to Grace Therapeutics, Inc. (Grace Therapeutics).

Acasti Announces First Fiscal Quarter 2025 Financial Results, Provides Business Update
globenewswire.com09 August 2024 Sentiment: POSITIVE

PRINCETON, N.J., Aug. 09, 2024 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (Nasdaq: ACST) (Acasti or the Company), a late-stage, biopharma company advancing GTX-104, its novel injectable formulation of nimodipine that addresses high unmet medical needs for a rare disease, aneurysmal subarachnoid hemorrhage (aSAH), today announced financial results and business highlights for the quarter ended June 30, 2024.

Is Acasti Pharma (ACST) Outperforming Other Medical Stocks This Year?
zacks.com10 July 2024 Sentiment: POSITIVE

Here is how Acasti Pharma (ACST) and Cigna (CI) have performed compared to their sector so far this year.

Acasti Announces Year-End 2024 Financial Results, Provides Business Update
globenewswire.com21 June 2024 Sentiment: POSITIVE

PRINCETON, N.J., June 21, 2024 (GLOBE NEWSWIRE) --  Acasti Pharma Inc. (Nasdaq: ACST) (Acasti or the Company), a late-stage, biopharma company advancing GTX-104, its novel injectable formulation of nimodipine that addresses high unmet medical needs for a rare disease, aneurysmal subarachnoid hemorrhage (aSAH), today announced financial results and business highlights for the year ended March 31, 2024.

Wall Street Favorites: 3 Penny Stocks With Strong Buy Ratings for June 2024
investorplace.com18 June 2024 Sentiment: POSITIVE

As the main stock indices like the S&P 500 and Nasdaq continue to climb, penny stocks are becoming attractive for those seeking significant returns. Despite their reputation for extreme price fluctuations and high risk, they offer the potential for impressive gains, especially in a bull market.

Acasti to Present GTX-104 Pharmacokinetic Comparison Data at Neurocritical Care Annual Meeting
GlobeNewsWire09 August 2023 Sentiment: POSITIVE

PRINCETON, N.J., Aug. 09, 2023 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (Nasdaq: ACST) ("Acasti" or the "Company"), a late-stage, biopharma company advancing GTX-104 its novel formulation of nimodipine that addresses the high unmet medical needs for a rare disease, aneurysmal subarachnoid hemorrhage (aSAH), today announced that a poster presenting a pharmacokinetic comparison of GTX-104 with oral nimodipine has been accepted for presentation at the 2023 Neurocritical Care Society (NCS) annual meeting, to be held in Phoenix, AZ August 15-18, 2023.

What type of business is Acasti Pharma?

Grace Therapeutics, Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal betamethasone spray for the treatment of ataxia-telangiectasia; and GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia. The company was formerly known as Acasti Pharma Inc. and changed its name to Grace Therapeutics, Inc. in October 2024. The company was incorporated in 2002 and is headquartered in Princeton, New Jersey.

What sector is Acasti Pharma in?

Acasti Pharma is in the Healthcare sector

What industry is Acasti Pharma in?

Acasti Pharma is in the Biotechnology industry

What country is Acasti Pharma from?

Acasti Pharma is headquartered in United States

When did Acasti Pharma go public?

Acasti Pharma initial public offering (IPO) was on 07 February 2012

What is Acasti Pharma website?

https://www.acastipharma.com

Is Acasti Pharma in the S&P 500?

No, Acasti Pharma is not included in the S&P 500 index

Is Acasti Pharma in the NASDAQ 100?

No, Acasti Pharma is not included in the NASDAQ 100 index

Is Acasti Pharma in the Dow Jones?

No, Acasti Pharma is not included in the Dow Jones index

When was Acasti Pharma the previous earnings report?

No data

When does Acasti Pharma earnings report?

The next expected earnings date for Acasti Pharma is 13 November 2024